Prosthetic joint infections - Pipeline Review, H1 2020

June 2020 | 66 pages | ID: P498AF90CDAEN
Global Markets Direct

Abstracts

Prosthetic joint infections - Pipeline Review, H1 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Prosthetic Joint infections - Pipeline Review, H1 2020, provides an overview of the Prosthetic Joint infections (Musculoskeletal Disorders) pipeline landscape.
Prosthetic joint infection (PJI) is one of the most serious complications of prosthetic joint implantation. Symptoms include pain or stiffness in joints, swelling, redness around the wound, fatigue and fever. Risk factors include age, prior arthroplasty, poor nutritional status, obesity, diabetes mellitus and advanced HIV disease. Treatment includes antimicrobial therapy.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Prosthetic Joint infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Prosthetic Joint infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 5 respectively.
Prosthetic Joint infections (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Prosthetic Joint infections (Musculoskeletal Disorders).
• The pipeline guide reviews pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Prosthetic Joint infections (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Prosthetic Joint infections (Musculoskeletal Disorders)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Prosthetic Joint infections (Musculoskeletal Disorders).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Prosthetic Joint infections (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Prosthetic Joint infections - Overview
Prosthetic Joint infections - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Prosthetic Joint infections - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Prosthetic Joint infections - Companies Involved in Therapeutics Development
Armata Pharmaceuticals Inc
Arrevus Inc
ContraFect Corp
Lumobiotics GmbH
Peptilogics Inc
Sonoran Biosciences Inc
Telephus Medical LLC
TenNor Therapeutics Ltd
Prosthetic Joint infections - Drug Profiles
(tobramycin + vancomycin SR) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APSA-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
APSA-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CF-296 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
exebacase - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
fusidic acid - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PLG-0206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Oncology and Infectious Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TNP-2092 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TPH-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Prosthetic Joint infections - Dormant Projects
Prosthetic Joint infections - Discontinued Products
Prosthetic Joint infections - Product Development Milestones
Featured News & Press Releases
Feb 25, 2020: Peptilogics announces CARB-X funding to accelerate development of first-in-class antibiotics to address the global threat of multi-drug resistant bacteria
Jan 20, 2020: TenNor Therapeutics received FDA orphan drug designation
Jan 13, 2020: ContraFect partners with leading orthopedic center in Europe to provide compassionate use of exebacase to patients with chronic staphylococcal prosthetic joint infections
Oct 15, 2018: Peptilogics receives regulatory approval to initiate first-in-human safety study for therapeutic peptide PLG0206
Aug 24, 2018: Peptilogics completes successful pre-IND meeting with the Food and Drug Administration for PLG0206 in Prosthetic Joint Infections
Jun 02, 2018: Peptilogics Receives Qualified Infectious Disease Product Designation from FDA for Lead Compound PLG0206 as a Treatment for Prosthetic Joint Infection
Oct 29, 2013: Cempra Receives U.S. Orphan Drug Designation for Taksta for Treatment of Prosthetic Joint Infections
Dec 14, 2012: Cempra Announces Initiation Of CEM-102 Phase II Clinical Trial In Patients With Prosthetic Joint Infections
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Prosthetic Joint infections, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Prosthetic Joint infections - Pipeline by Armata Pharmaceuticals Inc, H1 2020
Prosthetic Joint infections - Pipeline by Arrevus Inc, H1 2020
Prosthetic Joint infections - Pipeline by ContraFect Corp, H1 2020
Prosthetic Joint infections - Pipeline by Lumobiotics GmbH, H1 2020
Prosthetic Joint infections - Pipeline by Peptilogics Inc, H1 2020
Prosthetic Joint infections - Pipeline by Sonoran Biosciences Inc, H1 2020
Prosthetic Joint infections - Pipeline by Telephus Medical LLC, H1 2020
Prosthetic Joint infections - Pipeline by TenNor Therapeutics Ltd, H1 2020
Prosthetic Joint infections - Dormant Projects, H1 2020
Prosthetic Joint infections - Discontinued Products, H1 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Prosthetic Joint infections, H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products by Top 10 Targets, H1 2020
Number of Products by Stage and Top 10 Targets, H1 2020
Number of Products by Top 10 Mechanism of Actions, H1 2020
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
Number of Products by Top 10 Routes of Administration, H1 2020
Number of Products by Stage and Top 10 Routes of Administration, H1 2020
Number of Products by Top 10 Molecule Types, H1 2020
Number of Products by Stage and Top 10 Molecule Types, H1 2020

COMPANIES MENTIONED

Armata Pharmaceuticals Inc
Arrevus Inc
ContraFect Corp
Lumobiotics GmbH
Peptilogics Inc
Sonoran Biosciences Inc
Telephus Medical LLC
TenNor Therapeutics Ltd